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Abstract
Aim—The development of chemoradiation – the concurrent administration of chemotherapy and
radiotherapy – has led to significant improvements in local tumor control and survival. However, it
is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle)
therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation.
Method—A biodegradable and biocompatible lipid–polymer hybrid NP that is capable of delivering
both chemotherapy and radiotherapy was formulated.
Results—Using docetaxel, indium111 and yttrium90 as model drugs, we demonstrated that the
ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics
(100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate
cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher
therapeutic efficacy of ChemoRad NPs.
Conclusion—We believe that the ChemoRad NP represents a new class of therapeutics that holds
great potential to improve cancer treatment.
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The advent of concurrent administration of chemotherapy and radiotherapy (chemoradiation)
has significantly improved cancer care. Currently, it is the standard of treatment for many
cancers, including esophageal, gastric, head and neck, and rectal cancers [1]. However,
chemoradiation is limited by its higher (potentially life-threatening) toxicity, thereby
precluding patients with poor general health from undergoing treatment. One potential strategy
to improve chemoradiation utilizes advancements in drug delivery technology to improve
efficacy and lower toxicity of the treatment. In particular, advances in nanotechnology have
led to the development of nanoparticle (NP) drug-delivery vehicles, which can potentially
improve the codelivery of chemoradiation. NPs are particularly well suited for cancer
applications as they passively accumulate in tumors through the enhanced permeability and
retention effect [2]. The proof-of-principle was observed in liposomal formulations of
chemotherapeutics, such as Doxil, which demonstrated lower toxicity than their small
molecular counterparts [3]. Our group and other investigators have demonstrated that the
combination of biological targeting and NP delivery result in a higher concentration of
chemotherapeutics within cancer cells [4–12]. Considering the many favorable characteristics
of targeted NPs, we became interested in developing a targeted NP platform that is capable of
delivering both chemotherapy and radiotherapy. We hypothesized that such an NP may
improve efficacy and lower toxicity of chemoradiotherapy.
In this study, we report the development of what we believe to be the first multifunctional NP
platform intended for the codelivery of chemotherapeutics and therapeutic radioisotopes
(ChemoRad NP). Although previous studies have incorporated radioisotopes into NPs for
biodistribution and pharmacokinetics, none have utilized the NPs for the delivery of
chemoradiation [13]. The main challenge for engineering a ChemoRad NP lies in incorporating
therapeutic doses of radioisotopes into NPs without affecting NP characteristics, including
size, surface charge, stability and drug delivery profile. Potential compartments for
radioisotope incorporation include the NP surface, the NP core, or a combination of the two.
However, incorporating radioisotopes onto the NP surface would likely change the surface
charge and size of the NP [14]. Furthermore, adding the radioisotopes into the core can change
the drug encapsulation and drug release. Therefore, we chose to add radioisotopes into a layer
between the outer NP surface and core. To accomplish this, we chose to utilize a lipid–polymer
hybrid NP platform where such a layer is possible. The following design criteria were also
used in the engineering of the ChemoRad NP [15]:
• The NP platform is comprised of natural or biocompatible and biodegradable/
bioeliminable materials to facilitate potential clinical translation;
• The NPs should have minimal release of radioisotopes prior to reaching the tumor to
minimize potential toxicity;
• The NPs should have size range of 50–100 nm, which has been shown to be optimal
for tumor accumulation/targeting.
Based on these criteria, we developed the ChemoRad NP using a biodegradable poly (D,L-lactic-
co-glycolic acid) (PLGA) polymer and biocompatible lipids. We systematically examined the
structural morphology, size, stability, drug release profile and radioisotope chelation properties
of the ChemoRad NP, followed by evaluating its targeting ability and therapeutic effectiveness
using prostate cancer as a disease model.
Materials & methods
Materials
All chemicals were obtained from Sigma-Aldrich (MO, USA) unless otherwise noted. The
PLGA, 50/50 DL-lactide/glycolide, intravenous 0.55–0.75 (~50 kDa), was purchased from
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Lactel (AL, USA). DSPE–PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
carboxy(polyethylene glycol) 2000, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
diethylene-triamine-pentaacetate (1,2-ditetradecanoyl-sn-glycero-3-phosphoethanolamine
[DMPE]–diethylenetriaminepentaacetate [DTPA]) were purchased from Avanti Lipids (AL,
USA). Lecithin (soybean, refined, molecular weight: ~330 Da) was purchased from Alfa Aesar
(MA, USA). LNCaP and PC3 cell lines as well as tissue culture reagents were obtained from
ATCC (Manassas, VA, USA). Indium-111 (half-life 2.83 days) and Yttrium-90 (half-life 2.67
days) were purchased from Perkin Elmers (MA, USA).
Synthesis & characterization of ChemoRad NP
Lipid–polymer hybrid ChemoRad NPs were prepared through a single-step nanoprecipitation
method as previously described [16]. Briefly, the PLGA polymer was dissolved in acetonitrile
at a concentration of 1 mg/ml. (Lecithin + DMPE–DTPA)/DSPE–PEG (8.5;1.5, molar ratio)
with a weight ratio of 15% to the PLGA polymer was dissolved in 4% ethanol by weight
aqueous solution. The DMPE-DTPA/lecithin molar ratio ranged from 1:85 (1% DMPE-DTPA
surface) to 10:85 (10% DMPE–DTPA surface). The lecithin/DSPE-PEG/DMPE-DTPA
solution was heated to 65°C to ensure all lipids were in liquid phase. The resulting PLGA
solution was then added into the preheated lipid solution drop-wise under gentle stirring. The
mixed solution was vortexed vigorously for 3 min followed by gentle stirring for 2 h at room
temperature. The remaining organic solvent and free molecules were removed by washing the
NP solution three times using an Amicon Ultra-4 centrifugal filter (Millipore, MA, USA) with
a molecular weight cutoff of 10 kDa. To prepare drug-encapsulated NPs, docetaxel (Dtxl;
Sigma-Aldrich, MO, USA) was dissolved into the PLGA acetonitrile solution before the
nanoprecipitation process. We formulated NPs with 5–30% Dtxl by weight. To formulate
aptamer (Apt) targeted NPs, the A10 Apt was first conjugated to DSPE–PEG through 1-ethyl-3-
[3-dimethylaminopropyl] carbodiimide hydrochloride] (EDC) –N-hydroxysuccinimide (NHS)
coupling reaction. The A10 Apt targets the prostate specific membrane antigen (PSMA) with
high affinity and selectivity [17]. DSPE–PEG–COOH was first activated with EDC (25 μL,
400 mM) and sulfo-NHS (25 μL, 100 mM) for 15 min with gentle shaking in an aqueous
solution. Amine terminated Apt (RNA-TEC, Belgium) was then added to the solution. The
reaction was performed with gentle shaking for 4 h.
Characterization of ChemoRad NP
Nanoparticle size (diameter, nm) and surface charge (ζ-potential, mV) were obtained from
three repeat measurements by quasi-elastic laser light scattering with a ζPALS dynamic light
scattering detector (15 mW laser, incident beam = 676 nm; Brookhaven Instruments
Corporation, NY, USA). NP size and shape distribution were further characterized using
transmission electron microscopy. NP stability in serum was characterized by incubating 1 mg
of NP in 10% human plasma solution and monitoring changes in NP size over time.
Drug loading & release study
In total, 3 ml of NP phosphate buffered saline (PBS) solutions at a concentration of 5 mg/ml
were split equally into 30 Slide-A-lyzer MINI dialysis microtubes with a molecular weight
cutoff of 3500 Da (Pierce, IL, USA). These microtubes were dialyzed in 4 l of PBS buffer at
37 °C with gentle stirring. PBS buffer was changed every 24 h during the whole dialysis
process. At each data point, NP solutions from three microtubes were collected separately and
mixed with an equal volume of acetonitrile to dissolve the NPs. The resulting free Dtxl content
in each microtube was assayed using an Agilent (CA, USA) 1100 HPLC equipped with a
pentafluorophenyl column (Curosil-PFP, 250 × 4.6 mm, 5 μm; Phenomenex, CA, USA). Dtxl
absorbance was measured by a UV-Vis detector at 227 nm and a retention time of 12 min in
1 ml/min 50/50 acetonitrile/water mobile phase.
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The ChemoRad NP and radioisotope chelation studies were carried out in 50 μM ammonium
citrate buffer at pH 6. The chelation reactions were carried out in 37 °C for 45 min under gentle
stirring. The chelation efficiency was measured by using a thin-layer chromatography protocol
described by Cooper et al. [18]. Briefly, the Chemorad NPs chelated with radioisotopes were
added to a thin-layer chromatographic strip and allowed to dry. The thin-layer chromatographic
strip was then placed in a 5–10 ml of 0.1 M ammonium acetate, pH 6, containing 50 mM EDTA
solution (mobile phase) in a 10- to 15-cm-tall glass beaker or similar container so that it is 0.5
cm deep. When the solvent is approximately 5 mm from the top of the strip, it was removed
and dried. The strip was cut into two equal parts across the short axis. The radioactivity of the
upper and lower halves were counted. The chelation efficiency was calculated by the
percentage chelation efficiency equals counts on lower half of the strip divided by total counts,
times 100 %.
Chelation stability study
ChemoRad NP solutions at a concentration of 5 mg/mL (100 μCi 111In/mg and 5% Dtxl) were
split equally into Slide-A-lyzer MINI dialysis microtubes with a molecular weight cutoff of
3500 Da. These microtubes were dialyzed in 4 l of PBS buffer at 37°C with gentle stirring.
PBS buffer was changed every 24 h during the whole dialysis process. At each data point, NP
solutions from three microtubes were collected separately. The 111In content in the cells was
assayed in a Packard Tri-Carb Scintillation Analyzer.
Fluorescence microscopy
To visualize cellular uptake of Apt targeted lipid–polymer hybrid NPs using fluorescence
microscopy, a hydrophobic fluorescent dye, 22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino)-23,24-bisnor-5-cholen-3-ol (NBD)-cholesterol (Invitrogen, CA, USA) was
encapsulated. The fluorescence emission spectrum of NBD (excitation/emission = 460 nm/534
nm) was detected in the green channel (490 nm/528 nm) of a Delta Vision RT deconvolution
microscope. Prostate cancer cell lines, LNCaP and PC3, were grown in eight-well microscope
chamber slides to allow 70% confluence in 24 h (i.e., 40,000 cells per cm2). NPs were added
to achieve a final concentration of approximately 250 μg/ml (n = 4). Cells were incubated with
the NPs for 45 min at 37°C, washed two times with PBS (300 μL per well), fixed with 4%
formaldehyde, and mounted with nonfluorescent mounting medium 4′,6-diamidino-2-
phenylindole (DAPI; Vector Laboratory, Inc., CA, USA). The 45 min time-point was chosen
for the maximum observed difference between targeted NP uptake and nontargeted NP uptake
experiments. The cells were then imaged using a deconvolution microscope (Delta Vision RT,
Applied Precision, WA, USA).
MTS cell proliferation assay
LNCaP and PC3 cell lines were grown in 12-well plates to allow 70% confluence in 24 h (i.e.,
40,000 cells/cm2). Cells were incubated with the conjugates for 45 min at 37°C, washed and
further incubated in fresh growth media for a total of 72 h. Cell viability was assessed
colorimetrically with the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) reagent (Promega, CA, USA) following the standard
protocol provided by the manufacturer. The absorbance was read with a microplate reader at
490 nm.
After identifying the Apt–ChemoRad–Dtxl (5% Dtxl by weight) LD50 concentration for the
LNCaP cells, we used an MCNP 4C-Monte Carlo Code to calculate the amount of90Y for 6
Gy of radiation to each well [19]. Using È=0.646 MeV, T = 2.59 × 105 s, λ = 3.004 × 10−6
s−1 and m = 2.0 × 10−3 kg (per well), the absorbed dose per initial activity was obtained as 9.3
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× 10−6 Gy Bq−1. This translated into 100 μCi 90Y/mg NP for 50 μg of NP per well. For the in
vitro efficacy study, the cells were incubated with ChemoRad NP (no Dtxl or 90Y), Dtxl–
ChemoRad NP, Apt–Dtxl–ChemoRad NP, Apt-Dtxl–90Y–ChemoRad NP, Apt–90Y–
ChemoRad NP, and 90Y–ChemoRad NP.
Results & discussion
To engineer the ChemoRad NP, we chose to modify the lipid–polymer NP platform, which
has been shown to be an effective drug delivery vehicle [16]. Although there are several
strategies to incorporate radioisotopes into NP, we chose to utilize a metal chelator given the
high stability of metal radioisotope–chelator complex [20]. We added a lipid-chelator
conjugate, DMPE–DTPA, into a lipid–polymer NP platform. The final ChemoRad NP is
comprised of four main components:
• A hydrophobic polymeric core composed of PLGA that can be utilized to encapsulate
poorly water soluble chemotherapeutics;
• A lipid monolayer composed of lecithin on the surface of the polymeric core to
enhance drug retention;
• A hydrophilic polymeric shell composed of poly(ethylene glycol) (DSPE–poly
[ethylene glycol]) to enhance stability and circulation half-life of the NP, as well as
to provide a conjugation moiety to targeting ligands;
• A lipid chelator layer composed of DMPE-DTPA for the chelation of radioisotopes
(Figure 1A).
To validate that the addition of the DMPE–DTPA did not change the characteristics of the
lipid-polymer NP, the NP size and surface charge were examined with various concentrations
of DMPE–DTPA. The mean hydrodynamic diameters and the ζ-potential of ChemoRad NPs
with various DMPE–DTPA concentrations (1, 5 and 10%) were approximately 65 nm and
approximately 35 mV respectively, and did not vary significantly with the DMPE-DTPA
concentration (Table 1). Transmission electron microscopy confirmed the NPs are
monodisperse spherical particles with sizes near 65 nm and a narrow size distribution (Figure
1b).
Nanoparticle stability in vivo is crucial to its effectiveness as a drug delivery vehicle. The
ChemoRad NPs’ stability (1, 5, and 10% DMPE–DTPA) was characterized in 10% plasma
using the change in NP size as a surrogate for protein adsorption. PLGA NPs and lipid–polymer
NPs without DMPE–DTPA were used as negative and positive controls, respectively. PLGA
NPs are known to aggregate in plasma, whereas lipid–polymer NPs have been shown to be
stable [21]. As seen in Figure 1C, while the PLGA NPs aggregated in plasma as expected, the
ChemoRad NPs containing 1, 5 and 10% DMPE–DTPA maintained a stable size and did not
aggregate. The external layer of PEG is known to prevent the adsorption of proteins and the
interaction with the immune system [22].
To confirm that the addition of DMPE–DTPA did not vary the drug delivery capabilities of
the lipid-polymer NP, we chose to use Dtxl as a model chemotherapeutic. The drug loading
and drug encapsulation efficiency of the ChemoRad NP was quantified first. Using Dtxl to
PLGA weight ratios from 5 to 30%, we found the ChemoRad NP encapsulation efficiency was
approximately 60% (57–62%). The final drug load was up to 9% of the NP weight.
Furthermore, the drug loading and encapsulation efficiency did not change with respect to
DMPE–DTPA concentration (0, 1, 5 and 10%). Clinical Dtxl dose is 75 mg/m2 weekly, which
translates into a ChemoRad NP concentration of approximately 830 mg/m2, a concentration
achievable with the ChemoRad NP. Using ChemoRad NPs (5% DMPE–DTPA) containing
5% Dtxl by weight, we then studied the drug release profile of ChemoRad NPs. The 7-day
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release profile showed controlled release of Dtxl with first-order release kinetics, as shown in
Figure 2A. These results are consistent with the lipid-polymer NP platform as well as with
other polymeric NP drug delivery platforms [8,23].
To demonstrate that ChemoRad NP is capable of delivering radiotherapy, we chose yttrium-90,
a US FDA approved radiotherapeutic, as the model therapeutic radioisotope for our study
[24]. 111In, which is frequently utilized in place of 90Y for experimentation and dose
calculation, was used for the ChemoRad NP chelation studies [25]. The chelation efficiency
of the ChemoRad NPs was identified using ChemoRad NPs (1, 5 and 10% DMPE–DTPA).
Using 100 μCi of 111In per 1 mg of NP, the chelation efficiency of the ChemoRad NPs was
approximately 99% (98.7 ± 0.6%). We then conducted seven-day chelation stability studies,
which showed that there is minimal release of the 111In in the first 36 h and 80% of the dose
was still retained after 60 h (Figure 2b). The subsequent release of 111In is most consistent with
NP degradation. Our results confirmed that the ChemoRad NP has high chelation efficiency
and is capable of delivering clinical doses of radiotherapeutics (~100 mCi).
Our previous studies have demonstrated that the targeting ligand can promote intracellular
uptake of the NPs, leading to higher intracellular drug accumulation within cancer cell [9,10].
As proof of principle, we used prostate cancer as a model disease and conjugated the A10 RNA
Apt, which binds to the PSMA, to the ChemoRad NPs. We demonstrated target-specific uptake
of Apt-targeted ChemoRad NPs using two prostate cancer cells lines, LNCaP (PSMA+) and
PC3 (PSMA−) using in vitro visualization (Figure 3).
To quantify the preferential uptake of the targeted ChemoRad NPs as compared with non-
targeted ChemoRad NPs, we chelated 111In to the ChemoRad NPs and performed an in vitro
cell uptake study. Radioactivity from LNCaP cells incubated with Apt–ChemoRad-111In
demonstrated that approximately 16% (15.8 ± 0.5) of the NPs was taken up by the cells within
45 min. Compared to the other experimental arms, the LNCaP cells incubated with Apt–
ChemoRad-111In had nearly ten times of the radioactivity as that of the others (Figure 4). Based
on the differential uptake, targeted ChemoRad NP should improve efficacy and lower toxicity
of chemoradiation.
We validated the therapeutic efficacy of ChemoRad NPs using ChemoRad NPs containing
both Dtxl and 90Y and the MTS cell survival assay. We chose to utilize NPs containing 5%
DMPE–DTPA as each miligram of NP can chelate over 10 mCi of radioisotope. Using Apt-
ChemoRad NPs encapsulating 5% Dtxl by weight, we first identified the LD50 Apt–
ChemoRad–Dtxl concentration for the LNCaP cells, which was 25 mg/l (50 μg per well). We
then calculated the amount of 90Y chelate on ChemoRad NP that would result in approximately
6 Gy of radiation in each well. Based on the LD50 concentration of Apt–ChemoRad–Dtxl, the
required concentration of 90Y is 100 μCi per milligram of NP. Using ChemoRad NPs alone
without the addition of Dtxl or 90Y as negative controls, we incubated the LNCaP cells and
PC3 cells with Dtxl–ChemoRad NP, Apt–Dtxl– ChemoRad NP, Apt–Dtxl–90Y–ChemoRad
NP, Apt–90Y–ChemoRad NP and 90Y-ChemoRad NP. As demonstrated in Figure 5, the
targeted ChemoRad NP containing both chemotherapy and radiotherapy (Apt–Dtxl–90Y–
ChemoRad NP) has a dramatically higher level of cell killing of LNCaP cells when compared
with targeted NPs containing single agent or nontargeted NPs.
Conclusion
In summary, we have developed what we believe to be the first NP platform that can deliver
concurrent chemoradiation. The ChemoRad NP is composed entirely of biocompatible and
biodegradable materials. We have shown that it has excellent physical characteristics as a drug
delivery vehicle. We have also demonstrated that it can not only encapsulate and deliver
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chemotherapy effectively, but also chelate therapeutic radioisotopes with high efficiency.
Using the A10 Apt as a targeting ligand and prostate cancer as a model disease, we
demonstrated that the ChemoRad NP can deliver concurrent chemotherapy and radiotherapy
in a target-specific fashion, and the targeted concurrent chemoradiation from ChemoRad NP
has much higher therapeutic efficacy than other forms of treatment. These data suggest that
ChemoRad NP has the potential to be translated to clinical practice and improve
chemoradiotherapy. Further research including in vivo experiments are required to validate the
potential of ChemoRad NP.
Future perspective
We believe that the ChemoRad NP represents a novel class of therapeutics and has the potential
to improve chemoradiation for cancer treatment. However, the in vitro results will need to be
validated in vivo. We also believe this technology has the potential to make a significant impact
on different fields of oncology, since the ChemoRad NP can be utilized for the treatment of
many human cancers by functionalizing the NP with different targeting ligands.
Executive summary
• Our aim was to develop a novel nanoparticle (NP) platform that can deliver both
chemotherapy and radiotherapy (chemoradiation).
• ChemoRad NP is a biodegradable, biocompatible NP capable of delivering both
chemotherapeutics and radiotherapeutics efficiently.
• Using prostate cancer as a disease model, we demonstrated the biologically
targeted ChemoRad NPs containing both chemotherapeutic and radiotherapeutic
have higher therapeutic efficacy than nontargeted NPs and NPs containing a single
therapeutic.
• We believe the ChemoRad NP represents a novel class of therapeutics and has the
potential to improve chemoradiation for cancer treatment.
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(A) The ChemoRad nanoparticle (NP). (B) Transmission electron microscope of the
ChemoRad NPs that contains 5% DMPE–DTPA. (C) In vitro stability study of ChemoRad
NPs in 10% plasma. All ChemoRad NPs contain DSPE–PEG on their surface. Apt: Aptamer;
DMPE: 1,2-ditetradecanoyl-sn-glycero-3-phosphoethanolamine; DSPE:
Distearoylphosphatidylethanolamine-N-poly(ethylene glycol) 2000 (DSPE-PEG). DTPA:
Diethylenetriaminepentaacetate; PEG: Poly(ethylene glycol); PLGA: Poly (d,l-lactic-co-
glycolic acid).
Wang et al. Page 10













Figure 2. (A) 7-day docetaxel release study of docetaxel–ChemoRad nanoparticles
Drug loading was 5% docetaxel by weight (B) 7-day 111In release study of 111In-ChemoRad
nanoparticles. 100 μCi of 111In was chelated to each miligram of nanoparticle.
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Figure 3. Selective binding and uptake of aptamer-targeted ChemoRad nanoparticles (NPs) in PC3
and LNCaP cells
Fluorescent dye 22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3-
ol (green) was encapsulated in NPs. A10 aptamer-targeted ChemoRad NPs were selectively
delivered to PSMA–LNCaP cells (A), but not to prostate specific membrane antigen–PC3 cells
(C). Nontargeted ChemoRad NPs had minimal uptake in either cell line (B,D).
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Figure 4. Selective binding and uptake of Apt-targeted ChemoRad nanoparticles with 111In
A10 Apt-targeted ChemoRad NPs were selectively taken up by LNCaP cells but not by PC3
cells. Nontargeted ChemoRad NPs had minimal uptake in either cell line. *p < 0.001 using
paired t-test.
Apt: Aptamer; NP: Nanoparticle.
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Figure 5. MTS cell viability assay of nanoparticles incubated with PC3 and LNCaP cells
Cells incubated with ChemoRad NPs without Dtxl or 90Y were utilized as controls. Apt–
Dtxl–90Y–ChemoRad NPs (Apt–Dtxl–Y–NP) killed 80% of the LNCaP cells with minimal
effects in PC3 cells.
*p < 0.001 using paired t-test.
Apt: Aptamer; Dtxl: Docetaxel; NP: Nanoparticle.
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Table 1
Size and ζ potential of ChemoRad nanoparticles.
DTPA (%) Mean particlesize (nm)
ζ potential
(mV)
0 66 ± 1 −34 ± 1
1 64 ± 2 −35 ± 1
5 66 ± 2 −34 ± 2
10 65 ± 1 −35 ± 1
DTPA: Diethylene-triamine-penta-acetate.
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